We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
AusPAR: Pembrolizumab (rch)
Australian Public Assessment Report
Device/Product Name
Keytruda
Active ingredients
Pembrolizumab (rch)
AusPAR Date
Published
Submission Number
PM-2015-04712-1-4 and PM -2016-02325-1-4
Submission Type
Major variation (both submissions were for new indications)
Decision
Approved